Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for Migraine in CADASIL
NCT04334408Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Dec 2021
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of fremanezumab in migraine, sponsored by Mayo Clinic. Planned start Dec 2021; status: withdrawn.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04334408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04334408.